Immunomodulatory therapeutic proteins in COVID‐19: current clinical development and clinical pharmacology considerations

P Ji, J Chen, A Golding, NP Nikolov… - The Journal of …, 2020 - Wiley Online Library
Abstract The coronavirus disease 2019 (COVID‐19) pandemic caused by infection with
SARS‐CoV‐2 has led to more than 600 000 deaths worldwide. Patients with severe disease …

Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features

F Rommasi, MJ Nasiri, M Mirsaeidi - Molecular and cellular biochemistry, 2022 - Springer
The novel coronavirus pandemic has emerged as one of the significant medical-health
challenges of the current century. The World Health Organization has named this new virus …

Immunomodulation as a potent COVID-19 pharmacotherapy: Past, present and future

DM Hertanto, BS Wiratama, H Sutanto… - Journal of …, 2021 - Taylor & Francis
In the first year of its appearance, the 2019 coronavirus disease (COVID-19) has affected
more than 150 million individuals and killed 3 million people worldwide. The pandemic has …

Pharmaco-immunomodulatory therapy in COVID-19

JG Rizk, K Kalantar-Zadeh, MR Mehra, CJ Lavie… - Drugs, 2020 - Springer
The severe acute respiratory syndrome coronavirus 2 associated coronavirus disease 2019
(COVID-19) illness is a syndrome of viral replication in concert with a host inflammatory …

Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review

M Razmi, F Hashemi, E Gheytanchi… - International …, 2020 - Elsevier
The global panic of the novel coronavirus disease 2019 (COVID-19) triggered by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an urgent requirement …

Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19)

MW McCarthy - Expert Opinion on Pharmacotherapy, 2022 - Taylor & Francis
ABSTRACT Introduction SARS-CoV-2, the virus that causes COVID-19, elicits a variety of
host responses ranging from asymptomatic or mild illness in most people, to severe disease …

Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations

R Akter, MR Rahman, ZS Ahmed, A Afrose - Heliyon, 2023 - cell.com
The COVID-19 pandemic has inflicted millions of deaths worldwide. Despite the availability
of several vaccines and some special drugs approved for emergency use to prevent or treat …

From cytokine storm to cytokine breeze: did lessons learned from immunopathogenesis improve immunomodulatory treatment of moderate-to-severe COVID-19?

G Rondovic, D Djordjevic, I Udovicic, I Stanojevic… - Biomedicines, 2022 - mdpi.com
Complex immune response to infection has been highlighted, more than ever, during the
COVID-19 pandemic. This review explores the immunomodulatory treatment of moderate-to …

Immunomodulation: a broad perspective for patients' survival of COVID-19 infection

CF Adeboboye, BO Oladejo… - European Journal of …, 2020 - journals.tmkarpinski.com
The pathogenesis of the SARS-CoV-2 virus is yet to be well understood. However, patients
with the virus show clinical manifestations which are very similar to those of SARS-CoV and …

The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection

A Copaescu, O Smibert, A Gibson, EJ Phillips… - Journal of Allergy and …, 2020 - Elsevier
The coronavirus disease 2019 pandemic caused by severe acute respiratory syndrome
coronavirus 2 presents with a spectrum of clinical manifestations from asymptomatic or mild …